

# Histamine H4 Receptor - Pipeline Review, H1 2020

<https://marketpublishers.com/r/HD6297FA0F15EN.html>

Date: March 2020

Pages: 52

Price: US\$ 3,500.00 (Single User License)

ID: HD6297FA0F15EN

## Abstracts

Histamine H4 Receptor - Pipeline Review, H1 2020

### SUMMARY

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) pipeline Target constitutes close to 7 molecules. The latest report Histamine H4 Receptor - Pipeline Review, H1 2020, outlays comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - The histamine H4 receptor is a member of the G protein-coupled receptor super family. H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.

The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 4 respectively. Report covers products from therapy areas Dermatology, Immunology, Ear Nose Throat Disorders, Ophthalmology and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Acute Sensorineural Hearing Loss, Age Related Macular Degeneration, Allergic Conjunctivitis, Allergies, Cystic Fibrosis, Hearing Disorders, Idiopathic Pulmonary Fibrosis and Plaque Psoriasis (Psoriasis Vulgaris).

Furthermore, this report also reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)

The report reviews Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics and enlists all their major and minor projects

The report assesses Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Overview

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics

Development

Bioprojet SCR

Chrysalis Pharma SAS

JW Pharmaceutical Corp

Novartis AG

Sensorion SA

Sosei Heptares

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles

adriforant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

azasetron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Products

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or

Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Product Development Milestones

Featured News & Press Releases

Mar 16, 2020: Covid-19: Sensorion delays Phase II trial due to slow recruitment rate

Feb 18, 2020: Sensorion gets approval to add new sites to Phase II trial of SENS-401

Feb 03, 2020: Sensorion to attend and present at LSX World Congress 2020

Jan 30, 2020: Sensorion presents new SENS-401 preclinical data at ARO Midwinter Meeting 2020

Jan 10, 2020: Sensorion announces its presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference

Dec 23, 2019: Sensorion announces positive data safety monitoring board review of Phase 2 trial for SENS-401 in Sudden Sensorineural Hearing Loss

Dec 23, 2019: Sensorion announces €5.6m non-dilutive funding to support SENS-401 Phase 2 study in Sudden Sensorineural Hearing Loss French ministry of armed forces to participate in the study

Nov 20, 2019: Drug tested for sudden hearing loss

Nov 07, 2019: Sensorion announces an oral presentation of new SENS-401 preclinical data at ISiET 2019 in Hannover

Oct 23, 2019: Sensorion announce collaboration announces a poster presentation of new SENS-401 preclinical data at SFN 2019 in Chicago

Sep 11, 2019: Sensorion announces three presentations at IEB 2019 in Padua

Aug 27, 2019: LEO Pharma files IND application to FDA for a clinical study of JW1601/LP0190 in the US

Jul 11, 2019: Sensorion receives FDA IND Approval for Arazasetron (SENS-401)

Jun 28, 2019: Sensorion's PIP is EMA-approved for two indications

Mar 31, 2019: JW Pharmaceutical receives the Technology Export Award of the 20th Republic of Korea New Drug Development Awards

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indication, H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by Bioprojet SCR, H1 2020  
Pipeline by Chrysalis Pharma SAS, H1 2020  
Pipeline by JW Pharmaceutical Corp, H1 2020  
Pipeline by Novartis AG, H1 2020  
Pipeline by Sensorion SA, H1 2020  
Pipeline by Sosei Heptares, H1 2020  
Dormant Products, H1 2020  
Dormant Products, H1 2020 (Contd..1), H1 2020  
Dormant Products, H1 2020 (Contd..2), H1 2020  
Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

### COMPANIES MENTIONED

Bioprojet SCR

Chrysalis Pharma SAS

JW Pharmaceutical Corp

Novartis AG

Sensorion SA

Sosei Heptares

## I would like to order

Product name: Histamine H4 Receptor - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/HD6297FA0F15EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HD6297FA0F15EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970